Liver transplantation with allografts from hepatitis B core antibody‐positive donors: A new approach
Liver transplantation with allografts from hepatitis B core antibody‐positive donors: A new approach
复制标题
乙型肝炎核心抗体阳性供者的同种异体肝移植：一种新方法
DOI：
10.1053/jlts.2003.50190
复制
发表时间：
2003
影响因子：
4.6
通讯作者：
F. Pons‐Romero
中科院分区：
文献类型：
--
作者：
E. Fábrega;C. García‐Suarez;A. Guerra;A. Orive;F. Casafont;J. Crespo;F. Pons‐Romero
器官供体的持续短缺激发了广泛使用来自具有B型肝炎核心抗体的供体的肝同种异体移植物，尽管存在将B型肝炎病毒（HBV）感染传播给受体的潜在风险。在这里，我们报告了接受来自B型肝炎核心抗体阳性供体的肝脏的幼稚受体的方案。从1999年11月至2002年3月，在我院对73例患者进行了77例肝移植，其中7例接受了来自B型肝炎核心抗体阳性供体的肝脏。所有受者均接受10，000 U/d静脉注射HBIg 7天和100 mg/d拉米夫定，直到我们可以从供体样本（血清和肝组织）中获得HBV-DNA。如果供体样本的HBV‐DNA结果为阳性，患者将继续接受预防治疗，如果结果为阴性，我们将完成联合预防治疗。移植后，在移植后第7、15、30和90天以及每3个月对受者的血清和淋巴细胞中的HBV血清学标志物和HBV-DNA进行检测。所有7个供体器官的血清和肝组织中HBV-DNA均为阴性。因此，我们停止了所有接受者的联合预防（范围，7至10天）。在3年研究期间（范围，9 - 36个月），7例患者均未发生新发HBV感染。我们的方法是相当安全的，它似乎是非常有效的预防肝移植术后新发HBV感染
The enduring shortfall of organ donors has inspired the widespread utilization of hepatic allografts from donors with hepatitis B core antibodies in spite of the potential risk of transmitting hepatitis B virus (HBV) infection to the recipient. Here we report a protocol of naive recipients receiving livers from hepatitis B core antibody‐positive donors. From November, 1999 to March, 2002, 77 liver transplantations were performed in 73 patients at our institution, 7 of whom received livers from hepatitis B core antibody‐positive donors. All recipients received 10,000 U/d of intravenous HBIg for 7 days and 100 mg/d of lamivudine until we could obtain the HBV‐DNA from the donor samples (serum and liver tissue). If the results of the HBV‐DNA from the donor samples were positive, the patient would continue with prophylaxis and if they were negative we would finish the combined prophylaxis. After transplantation, HBV serologic markers and HBV‐DNA by polymerase chain reaction (PCR) in serum and lymphocytes were tested in the recipients on the seventh, fifteenth, thirtieth, and ninetieth days as well as every 3 months after transplantation. All seven donor organs were negative for HBV‐DNA in serum and liver tissue. Thus, we stopped the combined prophylaxis in all recipients (range, 7 to 10 days). None of the 7 patients developed de novo HBV infection over the 3‐year study period (range, 9 to 36 months). Our approach is reasonably safe, and it appears to be very effective in the prevention of de novo HBV infection after liver transplantation
DOI：
10.1073/pnas.83.6.1627
发表时间：
1986-03-01
影响因子：
11.1
作者：
TURKASPA, R;BURK, RD;SHAFRITZ, DA
通讯作者：
SHAFRITZ, DA